Lemonade Presents at FT Partners Conference; No New Disclosures Alter WAIT Rating

What happened

Lemonade, Inc. (LMND) presented at the FT Partners FinTech Conference on September 16, 2026, with management reiterating its strategic focus on scaling AI-driven underwriting, expanding autonomy-aware auto insurance, and reaching positive adjusted EBITDA by Q4 2026. The presentation did not surface new financial disclosures or materially change the company's prior guidance, as core metrics and the profitability timeline remain consistent with the February 2026 shareholder letter. Our latest deep-value analysis continues to rate LMND a WAIT at $51.85, reflecting a $3.9B market cap and a valuation that embeds a clean underwriting inflection without sufficient evidence of reserve stability. Q4 2025 results showed a 52% gross loss ratio and a $(4.6)M adjusted EBITDA loss, but the loss ratio included a favorable 9-point prior period development, masking an attritional loss ratio of 54%. With higher net retention under the reduced quota share (55% to 20%), the next 1-2 quarters are critical to confirm loss-ratio quality and progress toward the FY 2026 adjusted EBITDA loss target of ($52)M–($48)M.

Implication

The conference appearance reinforces management's commitment to the stated profitability path, but it does not de-risk the key concerns around reserve adequacy and the sustainability of reported loss ratios. With the stock trading at $51.85, near the low end of our base-case implied value of $55, the market already reflects skepticism about the profitability timeline, limiting downside if expectations are met but leaving little room for disappointment. Investors should monitor the next quarterly filings for any adverse reserve development and watch whether the attritional loss ratio trends downward without the 9-point PPD tailwind. The autonomy-aware pricing opportunity in Lemonade Car remains an upside catalyst, but until adoption metrics are disclosed in SEC filings, it should not be a primary basis for investment. Overall, the WAIT rating remains appropriate, with an attractive entry near $45 and a reassessment window of 3-6 months, contingent on evidence of clean underwriting progress.

Thesis delta

No change to the fundamental thesis: the conference presentation reiterated prior guidance without new data. Our WAIT rating is maintained, as the key risks—reserve quality, profitability timing, and autonomy adoption—are unchanged. We continue to require 1-2 quarters of clean loss-ratio data before reassessing.